865

ENDOGENOUS GLUCOCORTICOIDS PROTECT FROM HELICOBACTER-INDUCED AUTOIMMUNE GASTRITIS

Date
May 20, 2024

Gastric cancer is the 4th leading cause of cancer deaths worldwide. Helicobacter pylori infection is the primary risk factor for gastric cancer. In the United States, gastric cancer rates have been declining for several decades, likely due to reduced H. pylori infection rates. However, over the last 20 years, there has been a significant increase in the incidence of gastric cancer among young Caucasian women. This rise in cases is distinct because these patients typically present with autoimmune gastritis (AIG) and lack active H. pylori infections. H. pylori infection is linked to the increased risk of a host of autoimmune diseases, but the mechanisms controlling AIG development in these patients remain unknown. In this study, we investigated how the anti-inflammatory hormones glucocorticoids control the gastric inflammatory response to H. felis infection. Glucocorticoids were depleted systemically by bilateral adrenalectomy (ADX). Loss of glucocorticoids significantly increased gastric CD4+ T cell infiltration and Ifng production in response to H. felis infection compared to adrenal-intact felis-infected controls. Moreover, ADX mice exhibited a significant reduction of regulatory T cells. Importantly, the increased inflammation induced by ADX led to H. felis eradication by 2 months post-challenge while intact mice remained colonized. Despite eradicating H. felis, inflammation persisted in ADX mice for up to 1 year post-challenge, and ADX mice developed dysplasia. Next, serum was screened for self-reactive antibodies to investigate potential mechanisms driving the persistent gastric inflammation. Both adrenal-intact and ADX felis-challenged female mice exhibited self-reactive IgM antibodies in their sera, but self-reactive IgG was only detected in ADX mice, suggesting that self-reactive T cells facilitated antibody class switching. Together, these data suggest that glucocorticoids limit the intensity of the gastric inflammatory response to Helicobacter infection, allowing bacterial persistence but protecting from the development of autoimmunity. Moreover, our results suggest that endocrine disruption may increase the risk of AIG development.

Tracks

Related Products

Thumbnail for TARGETED IN VIVO COMPETITION AMONG CO-INFECTING HELICOBACTER PYLORI STRAINS INCREASES CAGA-DEPENDENT INFLAMMATION, INJURY, AND CARCINOGENESIS WITHIN THE CONTEXT OF IRON DEFICIENCY
TARGETED IN VIVO COMPETITION AMONG CO-INFECTING HELICOBACTER PYLORI STRAINS INCREASES CAGA-DEPENDENT INFLAMMATION, INJURY, AND CARCINOGENESIS WITHIN THE CONTEXT OF IRON DEFICIENCY
_Helicobacter pylori _is the strongest known risk factor for gastric cancer, and pathologic outcomes are mediated via complex interactions among _H. pylori _virulence factors, host immune responses, and the exposome…
Thumbnail for HYPUSINATION IN INTESTINAL EPITHELIAL CELLS PREVENTS COLON CARCINOGENESIS ASSOCIATED WITH APC DELETION
HYPUSINATION IN INTESTINAL EPITHELIAL CELLS PREVENTS COLON CARCINOGENESIS ASSOCIATED WITH APC DELETION
INTRODUCTION: The enzyme deoxyhypusine synthase (DHPS) conjugates the N-terminal moiety of the polyamine spermidine to the lysine-50 residue of eukaryotic translation initiation factor 5A (EIF5A) to form a unique amino acid, hypusine…
Thumbnail for TARGETING HYPOXIA-INDUCIBLE FACTOR-1 ALPHA (HIF-1α) SUPPRESSES GASTRIC CARCINOGENESIS VIA ATTENUATION OF BOTH <i>HELICOBACTER PYLORI </i>VIRULENCE AND PROINFLAMMATORY HOST RESPONSES
TARGETING HYPOXIA-INDUCIBLE FACTOR-1 ALPHA (HIF-1α) SUPPRESSES GASTRIC CARCINOGENESIS VIA ATTENUATION OF BOTH <i>HELICOBACTER PYLORI </i>VIRULENCE AND PROINFLAMMATORY HOST RESPONSES
INTRODUCTION. Our previous study reported a significant increase in metachronous recurrence of early gastric cancer after endoscopic submucosal dissection due to CD44v9-positive cancer stem-like cells in _H. pylori_-infected stomach tissue (_BR. J. CANCER_ 109:379, 2013)…
Thumbnail for EVALUATION OF THE SAFETY AND EFFICACY OF EFLORNITHINE (DIFLUOROMETHYLORNITHINE, DFMO) IN PATIENTS WITH GASTRIC PREMALIGNANT CONDITIONS IN THE HIGH INCIDENCE AREAS OF LATIN AMERICA
EVALUATION OF THE SAFETY AND EFFICACY OF EFLORNITHINE (DIFLUOROMETHYLORNITHINE, DFMO) IN PATIENTS WITH GASTRIC PREMALIGNANT CONDITIONS IN THE HIGH INCIDENCE AREAS OF LATIN AMERICA
BACKGROUND. Gastric adenocarcinoma (GAC) is the third leading global cause of cancer mortality and the leading infection-associated cancer. In the U.S., GAC represents a major cancer disparity, with incidence rates 2-3X in non-white populations…